Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

Q&A med Genmab A/S, 26 Februar Kl. 14:30 Læs mere her
      

Immune terapi


81002 Thorkild01 20/1 2020 20:27
3
Oversigt

Fantastisk nyhed hørt på BBC. Desværre går der jo nok mindst 10 år før, man får diverse godkendelser på plads, men alligevel en fantastisk nyhed.

https://www.bbc.com/news/health-51182451



20/1 2020 21:45 tommycarstensen 281003



Thorkild01 Spaendende. Tak.

"Why is this significant?

T-cell cancer therapies already exist and the development of cancer immunotherapy has been one of the most exciting advances in the field.

The most famous example is CAR-T - a living drug made by genetically engineering a patient's T-cells to seek out and destroy cancer.

CAR-T can have dramatic results that transform some patients from being terminally ill to being in complete remission.

However, the approach is highly specific and works in only a limited number of cancers where there is a clear target to train the T-cells to spot.

And it has struggled to have any success in "solid cancers" - those that form tumours rather than blood cancers such as leukaemia.

The researchers say their T-cell receptor could lead to a "universal" cancer treatment."

To eksisterende terapier, der begge koster i omegnen af en halv million dollar, er:

Yescarta® fra Kite Pharma (nu Gilead Sciences)
https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
https://www.yescarta.com/

Kymriah® fra Novartis
https://en.wikipedia.org/wiki/Tisagenlecleucel
https://www.kymriah.com/



21/1 2020 14:35 Peter.k 181013



Dejligt med sådan nogle nyheder - tak for deling!



TRÅDOVERSIGT